Anavex life sciences to participate in the cantor virtual rare orphan disease summit

New york, march 28, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that anavex management team will participate in the rare neurodevelopmental disorders panel at the cantor virtual rare disease summit on wednesday, march 30, 2022 at 11:00 am et.
AVXL Ratings Summary
AVXL Quant Ranking